1) La vaccinazione anti-COVID riduce contagi e trasmissione, tutelando la comunità?
No, per niente.
2) Era comunque sostenibile scientificamente la riduzione vaccinale di contagi e trasmissione quando l’obbligo è stato ripetutamente prorogato?
Di nuovo la risposta è no, per niente.
Nel documento seguente si trovano le prove scientifiche a supporto.
Di seguito, tutta la Bibliografia per l'articolo comparso su Visione :
[1] Day M. Covid-19: Stronger warnings are needed to curb socialising after vaccination, say doctors and behavioural scientists BMJ 2021; 372 :n783 doi:10.1136/bmj.n783
[2 ] Hunter PR and Brainard J (2021) Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel. doi: https://doi.org/10.1101/2021.02.01.21250957
[3] Craig C. Thinking beyond behavioural change as an explanation for increased COVID post vaccination. 26 March 2021. Rapid Response to: Day M. Covid-19: Stronger warnings are needed to curb socialising after vaccination, say doctors and behavioural scientists. BMJ 2021; 372:n783 doi:10.1136/bmj.n783.
[4] Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med 2021 Dec 9;385(24):e83. doi: 10.1056/NEJMoa2114114.
[5] Sheikh A, Kerr S, Woolhouse M, et al. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis 2022; 22: 959–66. https://doi.org/10.1016/ S1473-3099(22)00141-4.
[6] Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021 Jan;2(1):e13-e22. doi: 10.1016/S2666-5247(20)30172-5.
[7] Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022 Jun;22(6):781-790. doi: 10.1016/S1473-3099(22)00143-8.
[8] Gazit S, Shlezinger R, Perez G, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. Clin Infect Dis. 2022 Aug 24;75(1):e545-e551. doi: 10.1093/cid/ciac262.
[9] Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med. 2022 Jul 7;387(1):21-34. doi: 10.1056/NEJMoa2203965.
[10] Nordström P, Ballin M, Nordström A. (2022). Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. The Lancet. 399. 10.1016/S0140-6736(22)00089-7.
[11] Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study BMJ 2022; 376:e069052 doi:10.1136/bmj-2021-069052.
[12] Hansen CH, Schelde AB, Moustsen-Helm IR, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study.medRxiv 2021.12.20.21267966; doi: https://doi.org/10.1101/2021.12.20.21267966.
[13] Istituto Superiore di Sanità EpiCentro - L'epidemiologia per la sanità pubblica. Coronavirus - news (iss.it)
[14] Commissione Medico Scientifica Indipendente. Home | CMSi (cmsindipendente.it) Comunicato 5 CMSi (11-1-23)_0.pdf (cmsindipendente.it)
[15] UK Health Security Agency.COVID-19 vaccine quarterly surveillance reports (September 2021 to June 2023). COVID-19 vaccine quarterly surveillance reports (September 2021 to June 2023) - GOV.UK (www.gov.uk)
[16] Tamandjou C, Auvigne V, Schaeffer J, et al. Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. Vaccine. 2023 Apr 24;41(17):2754-2760. doi: 10.1016/j.vaccine.2023.03.031.
[17] Shrestha NK, Burke PC, Nowacki AS, et al. Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine. Open Forum Infect Dis. 2023 Apr 19;10(6):ofad209. doi: 10.1093/ofid/ofad209.
[18] Chemaitelly H, Ayoub HH, Tang P, et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect Dis. 2023 Jul;23(7):816-827. doi: 10.1016/S1473-3099(23)00058-0.
[19] Chemaitelly H, Nagelkerke N, Ayoub HH, et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J Travel Med. 2022 Dec 27;29(8):taac109. doi: 10.1093/jtm/taac109.
[20] Woodbridge Y, Amit S, Huppert A, et al. Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection. Nat Commun. 2022 Nov 7;13(1):6706. doi: 10.1038/s41467-022-33096-0.
[21] CDC. Brown C.M. et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
Weekly / August 6, 2021 / 70(31);1059-1062.
[22] CDC Director Inadvertently Destroys Argument for Vaccine Passports By Surprisingly Saying Vaccines Do Not ‘Prevent Transmission’ [VIDEO] - NewsRescue.com. August 8, 2021.
[23] WGAME_V_EN_3D_隐藏狙击草地版_CB_130_1920x1080_38s_231027_NR_512679 (youtube.com)
e Tony Fauci inglese.odt (assis.it)